A genetic study of lymphoma tumors has revealed the importance of a signaling pathway long suspected of playing a role in certain forms of the disease. DNA mutations were found in two components of the B-cell receptor-signaling pathway in a subset of patients with diffuse large B-cell lymphomas (DLBCL). In additional experiments, the researchers showed that drugs could kill these lymphoma cells by blocking signals from this pathway.